The U.S. Food and Drug Administration declined to approve Alimera Sciences Inc’s experimental drug to treat retinal swelling in its current form, sending the biopharmaceutical company’s shares down 41 percent in after-market trade.
All News, Video and Posts related to SECTOR: Health Care
Popular Posts:
- Roche says skin cancer drug substantially shrinks
- Roche says skin cancer drug substantially shrinks
- Roche says skin cancer drug substantially shrinks
- Roche says skin cancer drug substantially shrinks
- FDA delays decision on lupus drug Benlysta